BMXMF:OTC-bioMérieux S.A (USD)

COMMON STOCK | Diagnostics & Research | OTC

Last Closing Price

USD 91.50

Change

0.00 (0.00)%

Market Cap

USD 11.07B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

bioMérieux S.A (BMXMF) Stock Analysis:
Based on the bioMérieux S.A stock forecasts from 0 analysts, the average analyst target price for bioMérieux S.A is not available over the next 12 months. bioMérieux S.A’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of bioMérieux S.A is Neutral, which is based on 8 positive signals and 8 negative signals. At the last closing, bioMérieux S.A’s stock price was USD 91.50. bioMérieux S.A’s stock price has changed by -0.27% over the past week, -10.73% over the past month and -17.83% over the last year.

No recent analyst target price found for bioMérieux S.A
No recent average analyst rating found for bioMérieux S.A

About

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiova ...Read More

Company Website : https://www.biomerieux.com

Address : 376 Chemin De l?Orme, Marcy l'Étoile, France, 69280

Employees : 12,084

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : -0.13

52 Week High : 148.50

52 Week Low : 87.13

200 Day Moving Average : 118.31

50 Day Moving Average : 100.75

Shares Held By Insiders : 64.12%

Shares Held by Institutions : 18.50%

Dividend Yield : 0.81%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LZAGF Lonza Group Ltd

-24.76 (-4.45%)

 USD42.00B 13.99 65.64
LZAGY Lonza Group Ltd

-0.35 (-0.64%)

 USD39.72B 13.29 65.64
ERFSF Eurofins Scientific SE

+1.86 (+2.10%)

 USD17.70B 22.50 11.05
SKHHY Sonic Healthcare Limited

-0.19 (-0.75%)

 USD12.09B 12.09 4.87
SKHCF Sonic Healthcare Limited

+0.24 (+0.96%)

 USD11.94B 11.84 4.93
DSRLF DiaSorin S.p.A

+7.66 (+6.65%)

 USD6.47B 20.24 17.77
MRCHF H.U. Group Holdings Inc

N/A

 USD1.49B 6.35 0.03
EPLYF EPS Holdings Inc

N/A

 USD0.72B 25.75 0.10
IDGXF Integrated Diagnostics Holding..

N/A

 USD0.63B 18.81 0.21
ANPCY ANGLE plc

N/A

 USD0.35B N/A N/A

ETFs Containing BMXMF

Symbol Name Weight Mer Price(Change) Market Cap
DRDR:LSE iShares IV Public Limited.. 0.00 % 0.40 %

+0.75 (+0.13%)

 USD1.34B
HEAL:LSE iShares IV Public Limited.. 0.00 % 0.40 %

+0.02 (+0.33%)

 USD1.34B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.59 %

+0.01 (+0.16%)

 USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -34.64% 38% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.64% 35% F 24% F
Trailing 12 Months  
Capital Gain -22.98% 67% D+ 51% F
Dividend Return 0.63% 30% F 5% F
Total Return -22.34% 67% D+ 49% F
Trailing 5 Years  
Capital Gain -46.02% 47% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.02% 47% F 33% F
Average Annual (5 Year Horizon)  
Capital Gain 8.36% 27% F 46% F
Dividend Return 0.13% 23% F 17% F
Total Return 8.50% 25% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 41.00% 86% B 55% F
Risk Adjusted Return 20.73% 35% F 43% F
Market Capitalization 11.07B 90% A- 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.17 29% F 38% F
Price/Book Ratio 3.28 53% F 29% F
Price / Cash Flow Ratio 13.65 16% F 12% F
EV/EBITDA 10.53 35% F 27% F
Management Effectiveness  
Return on Equity 21.15% 80% B- 86% B
Return on Invested Capital 20.79% 77% C+ 82% B-
Return on Assets 11.72% 94% A 94% A
Debt to Equity Ratio 11.62% 37% F 65% D
Technical Ratios  
Dividend Yield 0.81% 21% F 6% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.13 78% C+ 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector